195 related articles for article (PubMed ID: 18715779)
1. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.
Shah N; Pang B; Yeoh KG; Thorn S; Chen CS; Lilly MB; Salto-Tellez M
Eur J Cancer; 2008 Oct; 44(15):2144-51. PubMed ID: 18715779
[TBL] [Abstract][Full Text] [Related]
2. PIM1 kinase as a target for cancer therapy.
Merkel AL; Meggers E; Ocker M
Expert Opin Investig Drugs; 2012 Apr; 21(4):425-36. PubMed ID: 22385334
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
4. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.
Isaac M; Siu A; Jongstra J
Drug Resist Updat; 2011; 14(4-5):203-11. PubMed ID: 21601509
[TBL] [Abstract][Full Text] [Related]
5. Insights from Pim1 structure for anti-cancer drug design.
Ogawa N; Yuki H; Tanaka A
Expert Opin Drug Discov; 2012 Dec; 7(12):1177-92. PubMed ID: 23004574
[TBL] [Abstract][Full Text] [Related]
6. Identification of quinones as novel PIM1 kinase inhibitors.
Schroeder RL; Goyal N; Bratton M; Townley I; Pham NA; Tram P; Stone T; Geathers J; Nguyen K; Sridhar J
Bioorg Med Chem Lett; 2016 Jul; 26(13):3187-3191. PubMed ID: 27173800
[TBL] [Abstract][Full Text] [Related]
7. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
8. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.
Holder SL; Abdulkadir SA
Curr Cancer Drug Targets; 2014; 14(2):105-14. PubMed ID: 24274399
[TBL] [Abstract][Full Text] [Related]
9. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
Liang C; Li YY
Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
[TBL] [Abstract][Full Text] [Related]
10. Pim kinase inhibitors: a survey of the patent literature.
Morwick T
Expert Opin Ther Pat; 2010 Feb; 20(2):193-212. PubMed ID: 20100002
[TBL] [Abstract][Full Text] [Related]
11. Using insights into Pim1 structure to design new anticancer drugs.
Schenone S; Tintori C; Botta M
Curr Pharm Des; 2010; 16(35):3964-78. PubMed ID: 21158732
[TBL] [Abstract][Full Text] [Related]
12. The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction.
Ye C; Zhang C; Huang H; Yang B; Xiao G; Kong D; Tian Q; Song Q; Song Y; Tan H; Wang Y; Zhou T; Zi X; Sun Y
Cell Physiol Biochem; 2018; 48(3):1230-1244. PubMed ID: 30045021
[TBL] [Abstract][Full Text] [Related]
13. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
De Donato M; Mariani M; Petrella L; Martinelli E; Zannoni GF; Vellone V; Ferrandina G; Shahabi S; Scambia G; Ferlini C
J Cell Physiol; 2012 Mar; 227(3):1034-41. PubMed ID: 21520077
[TBL] [Abstract][Full Text] [Related]
14. Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors.
Olla S; Manetti F; Crespan E; Maga G; Angelucci A; Schenone S; Bologna M; Botta M
Bioorg Med Chem Lett; 2009 Mar; 19(5):1512-6. PubMed ID: 19179076
[TBL] [Abstract][Full Text] [Related]
15. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
Nakano H; Saito N; Parker L; Tada Y; Abe M; Tsuganezawa K; Yokoyama S; Tanaka A; Kojima H; Okabe T; Nagano T
J Med Chem; 2012 Jun; 55(11):5151-64. PubMed ID: 22540945
[TBL] [Abstract][Full Text] [Related]
16. PIM1: a promising target in patients with triple-negative breast cancer.
Zhao W; Qiu R; Li P; Yang J
Med Oncol; 2017 Aug; 34(8):142. PubMed ID: 28721678
[TBL] [Abstract][Full Text] [Related]
17. Why target PIM1 for cancer diagnosis and treatment?
Magnuson NS; Wang Z; Ding G; Reeves R
Future Oncol; 2010 Sep; 6(9):1461-78. PubMed ID: 20919829
[TBL] [Abstract][Full Text] [Related]
18. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells.
Wang J; Anderson PD; Luo W; Gius D; Roh M; Abdulkadir SA
Oncogene; 2012 Apr; 31(14):1794-803. PubMed ID: 21860423
[TBL] [Abstract][Full Text] [Related]
19. Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets.
Rodríguez-González A; Ramírez de Molina A; Benítez-Rajal J; Lacal JC
Prog Cell Cycle Res; 2003; 5():191-201. PubMed ID: 14593713
[TBL] [Abstract][Full Text] [Related]
20. Kinase PIM1 promotes prostate cancer cell growth via c-Myc-RPS7-driven ribosomal stress.
Zhang C; Qie Y; Yang T; Wang L; Du E; Liu Y; Xu Y; Qiao B; Zhang Z
Carcinogenesis; 2019 Mar; 40(1):52-60. PubMed ID: 30247545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]